Stryker Corporation : Stryker Announces Definitive Offer to Acquire Trauson Holdings Company Limited

 Stryker Corporation : Stryker Announces Definitive Offer to Acquire Trauson
                           Holdings Company Limited

Kalamazoo, Michigan - January 17, 2013 - Stryker Corporation (NYSE:SYK) and
Trauson Holdings Company Limited (SEHK:0325.HK) announced today that Stryker
will make a voluntary general offer to acquire all the shares of Trauson for
HK$7.50 per ordinary share for a total consideration of $764 million in an all
cash transaction, representing an enterprise value of approximately $685
million. Trauson's controlling shareholder, Luna Group, has undertaken to
accept the offer from Stryker by tendering 61.7% of the Trauson shares towards
the offer. Founded in China in 1986 by Chairman Fuqing Qian, Trauson had sales
in 2011 approximating $60 million and is the leading trauma manufacturer in
China and a major competitor in the spine segment. Stryker and Trauson have
maintained a relationship under an OEM agreement for instrumentation sets
since 2007. With this acquisition, Stryker will expand its presence in a key
emerging market with a product portfolio and pipeline that is targeted at the
large and fast growing value segment of the Chinese orthopaedic market.

"The acquisition of Trauson is a critical step toward broadening our presence
in China and developing a value segment platform for the emerging markets
through a well established brand," said Kevin A. Lobo, President and Chief
Executive Officer. "The acquisition of a leading player in the Chinese trauma
and spine market underscores our commitment to strengthening our presence
globally. With its research and development expertise, manufacturing
capabilities and strength of its distribution network, Trauson is a compelling
opportunity for Stryker to drive growth in China and other emerging markets
for years to come."

"I am very proud to have worked with everyone associated with Trauson to build
the company from its beginning 27 years ago into the largest orthopaedic
products producer in China," said Chairman Fuqing Qian."The orthopaedics
market in China has great growth potential. The combined scale, local and
global expertise, complementary product offerings and market breadth of
Trauson and Stryker will create significant competitive advantages in the
increasingly dynamic orthopaedic industry and provide a platform to fully
realize the future growth opportunities in China and globally."

The closing of the transaction is subject to customary conditions. Upon
closing, the transaction is expected to be neutral to Stryker's 2013 diluted
net earnings per share excluding acquisition and integration-related charges
and accretive thereafter. The transaction is expected to close by the end of
the second quarter of 2013.

Barclays Capital served as Stryker's exclusive financial advisor and Sullivan
& Cromwell served as outside legal counsel for Stryker in connection with this

Stryker is one of the world's leading medical technology companies and is
dedicated to helping healthcare professionals perform their jobs more
efficiently while enhancing patient care. The Company offers a diverse array
of innovative medical technologies including reconstructive implants, medical
and surgical equipment, and neurotechnology and spine products to help people
lead more active and more satisfying lives. For more information about
Stryker, please visit


For media inquiries please contact:
Yin Becker, Stryker Corporation, 201-831-5000 or

For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or

Forward-Looking Statements

This press release contains information that includes or is based on
forward-looking statements within the meaning of the federal securities law
that are subject to various risks and uncertainties that could cause our
actual results to differ materially from those expressed or implied in such
statements. Such factors include, but are not limited to: weakening of
economic conditions that could adversely affect the level of demand for our
products; pricing pressures generally, including cost-containment measures
that could adversely affect the price of or demand for our products; changes
in foreign exchange markets; legislative and regulatory actions; unanticipated
issues arising in connection with clinical studies and otherwise that affect
U.S. Food and Drug Administration approval of new products; changes in
reimbursement levels from third-party payors; a significant increase in
product liability claims; the ultimate total cost with respect to the
Rejuvenate and ABG II matter; the impact of investigative and legal
proceedings and compliance risks; resolution of tax audits; the impact of the
federal legislation to reform the United States healthcare system and the 2.3
percent medical device excise tax; changes in financial markets; changes in
the competitive environment; our ability to integrate acquisitions, including
the acquisition of Trauson Holdings Company Limited; and the Company's ability
to realize anticipated cost savings as a result of workforce reductions and
other restructuring activities. Additional information concerning these and
other factors are contained in our filings with the U.S. Securities and
Exchange Commission, including our Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q.


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Stryker Corporation via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.